Landos Biopharma Inc logo

Landos Biopharma Inc Share Price (NASDAQ: LABP)

▲

-22.93

(-100%)

Last updated on

Bell Icon

This instrument is not available for trading on the INDmoney app on 22 May 2024

Check the interactive Landos Biopharma Inc Stock chart to analyse performance

Landos Biopharma Inc Key Stats

Check Landos Biopharma Inc key stats like market cap, P/E ratio, EPS, Dividend Yield, and more.

Previous Close
$22.93
Open
$22.93
Market Capitalization
$69.4M
Today's Volume
$50.9K
Revenue TTM
$0.0
EBITDA
$-22.2M
Earnings Per Share (EPS)
$-4.0
Profit Margin
0.0%
Quarterly Earnings Growth YOY
0.0%
Return On Equity TTM
-70.67%

Global Institutional Holdings in Landos Biopharma Inc

  • Name

    Holdings %

  • Perceptive Advisors LLC

    47.67%

  • Deltec Asset Management LLC

    1.60%

  • Macquarie Group Ltd

    0.47%

  • Geode Capital Management, LLC

    0.40%

  • Renaissance Technologies Corp

    0.36%

Analyst Recommendation on Landos Biopharma Inc Stock

Rating
Trend

Hold

    0%Buy

    62%Hold

    37%Sell

Based on 8 Wall street analysts offering stock ratings for Landos Biopharma Inc(by analysts ranked 0 to 5 stars)

About Landos Biopharma Inc

Landos Biopharma, Inc., a clinical-stage biopharmaceutical company, discovers and develops oral therapeutics for patients with autoimmune diseases. Its lead product candidate is NX-13, an oral gut-selective Nucleotide Oligomerization Domain (NLRX1), a mitochondria-associated receptor associated with the modulation of inflammatory cytokines that is in Phase 2 clinical trial to treat ulcerative colitis (UC) and completed Phase 1 to treat Crohn's disease (CD). The company's preclinical candidates in development include LABP-73, an oral and small molecule NLRX1 pathway agonist for the treatment of asthma and eosinophilic disorders; LABP-66 is an oral and small molecule NLRX1 pathway agonist for the treatment of multiple sclerosis and neurodegenerative disorders; and LABP-69, an oral PLXDC2 agonist for the treatment of rheumatoid arthritis, UC, and CD. The company has a license and collaboration agreement with LianBio Respiratory Limited to develop, manufacture, and commercialize omilancor and NX-13. Landos Biopharma, Inc. was incorporated in 2017 and is headquartered in Blacksburg, Virginia.
Organization
Landos Biopharma Inc
Employees
19
CEO
Mr. Gregory Oakes
Industry
Miscellaneous

Important FAQs about investing in LABP Stock from India :

What is Landos Biopharma Inc share price today?

Landos Biopharma Inc share price today is as on at the close of the market. Landos Biopharma Inc share today touched a day high of {{1_rba_end}} and a low of {{1_rba_st}}.

What is the 52 week high and 52 week low for Landos Biopharma Inc share?

Landos Biopharma Inc share touched a 52 week high of {{rba_end}} and a 52 week low of {{rba_st}}. Landos Biopharma Inc stock price today i.e. is closed at , lower by 100% versus the 52 week high.

How to invest in Landos Biopharma Inc Stock (LABP) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Landos Biopharma Inc on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Landos Biopharma Inc Shares .

What is the minimum amount required to buy Landos Biopharma Inc Stock (LABP) from India?

Indian investors can start investing in Landos Biopharma Inc (LABP) shares with as little as ₹92.408 or $1 (as of March 17, 2026) using the INDmoney app.
For example: If you want to invest $10 or ₹924.08 in Landos Biopharma Inc stock (as per the Rupee-Dollar exchange rate as on March 17, 2026). Learn more about fractional shares .

What are the returns that Landos Biopharma Inc has given to Indian investors in the last 5 years?

Landos Biopharma Inc stock has given 0.0% share price returns and 27.34% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?